RETRACTED: Tirzepatide and exercise training in obesity
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and physical fitness in prediabetic obese soldiers. METHODS: 61 obese men were randomly divided into six groups: Placebo; Tirzepatide 5 mg (T5); Tirzepatide 2.5 mg (T2.5); Hypertrophy, Strength, Power-Circuit Training+Placebo (Ex+P); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 5 mg (Ex+T5); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 2.5 mg (Ex+T2.5). All training groups performed aerobic training (AT) after resistance training. Subjects trained for six weeks, three sessions per week. Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), and muscle strength (chest press 1RM and leg press 1RM). Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR). To evaluate the differences between the groups, ANCOVA statistical method was used along with Bonferroni’s post hoc test, and the significance level was P < 0.05. R…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence indicates that structured physical activity, particularly resistance training, can mitigate these effects and optimize long-term metabolic outcomes (53–55).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [55]
In the citing paper
“Patients receiving GLP-1RAs experience significant weight loss but are also at increased risk of lean body mass and bone density loss.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [55]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“U/mL)]/405 [30].”
Psychophysical bases of perceived exertion
BORG, G. A. V. (1982) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198205000-00012 · Cited by 16,580 · cited 1×
“At the end of each phase, the participant was asked to rate the perceived exertion according to the Borg CR-10 scale [28].”
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212 · cited 1×
“The prevalence of obesity has been increasing worldwide [1, 2].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Tirzepatide injection was administered subcutaneously in the abdomen by a physician once a week using doses of 2.5 mg and 5 mg on a day when the subject did not exercise [25, 26].”
InfluentialBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GIP inhibits gastric secretory activity, stimulates insulin secretion, and exerts an insulin-like action on adipose tissue that inhibits lipolysis and promotes lipogenesis [39–41].”
Chooi, Y. C., Ding, C., & Magkos, F. (2019) · Metabolism · doi:10.1016/j.metabol.2018.09.005 · Cited by 2,737 · cited 1×
“The prevalence of obesity has been increasing worldwide [1, 2].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“…Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) are hormones released in the intestine in response to the intake of nutrients, and they can stimulate pancreatic beta cells to release insulin, thereby participating in the regulation of glucose homeostasis [13–15].”
(2014) · Journal of the Korean Medical Association · doi:10.5124/jkma.2014.57.11.899 · Cited by 2,566
Bioelectrical impedance analysis—part II: utilization in clinical practice
Kyle, U. G., Bosaeus, I., De Lorenzo, A. D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., et al. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.09.012 · Cited by 2,350 · cited 1×
“Before the test, the participants were asked to take off their clothes and wear a light and minimal outfit; keep jewelry and other metal and electronic equipment away from themselves and the device; Then wipe their hands and soles of their feet with a dry cloth and then place them on the device [27].”
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Integrating diet and physical activity when prescribing GLP-1s—Lifestyle factors remain crucial
Mehrtash, F., Dushay, J., & Manson, J. E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1794 · Cited by 44
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34
“…were on medications other than TZP that might interfere with body weight and BC [20,21,34–45]; (ii) two due to the short duration of the TZP treatment [46,47]; (iii) one because it had an open-label lead-in period [48]; and (iv) five for not reporting data related to WC [49–53] (Figure 1).”
BackgroundProkopidis, K. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70355 · Cited by 29
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
Metadata
- Authors
- Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., Baker, J. S., & Patel, D. I.
- Affiliations
- Hakim Sabzevari University (IR)
- Università Cattolica del Sacro Cuore (IT)
- Aja University of Medical Sciences (IR)
- University of South Florida (US)
- Islamic Azad University, Tehran (IR)
- Kansas State University (US)
- University of Turin (IT)
- Brandenburg University of Technology Cottbus-Senftenberg (DE)
- Hong Kong Baptist University (HK)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Bagherzadeh-Rahmani, Behnam
- ORCID
- Venue
- Clinical Hemorheology and Microcirculation
- Publisher
- SAGE Publications
- Published
- 2024-04-12
- Volume
- 87
- Issue
- 4
- Pages
- 465-480
- ISSN
- 1386-0291 (ISSN-L)
- 1875-8622
- OpenAlex
- W4394838417
- Semantic Scholar
- 3af0754f947c8a94b3169e1d6895bfa333f91908
- Cited by
- 21
- References
- 51
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 4
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2025-11-23)
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Clinical Hemorheology and Microcirculation (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Keywords
- GIP/GLP-1 receptor agonist, tirzepatide, obesity, prediabetes, resistance training, aerobic exercise, concurrent training, lipid profile, insulin resistance, body composition, cardiorespiratory fitness, muscle strength, military personnel, retracted article
- MeSH terms
- Adult, Humans, Insulin Resistance, Male, Obesity, Exercise, Body Mass Index, Resistance Training
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RETRACTED: Tirzepatide and exercise training in obesity. https://app.cochat.ai/papers/10.3233/ch-242134
- The paper
- Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., Baker, J. S., & Patel, D. I. (2024). RETRACTED: Tirzepatide and exercise training in obesity. Clinical Hemorheology and Microcirculation. https://doi.org/10.3233/ch-242134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.